A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer

A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer

Triple-negative breast cancer (TNBC) is one of the most aggressive and difficult to treat types of breast cancer. Here, a phase 2 clinical trial in TNBC patients reveals that the addition of lobaplatin to docetaxel and epirubicin regime improves pCR and ORR rates with tolerable side-effects.

Guardado en:
Detalles Bibliográficos
Autores principales: Xiujuan Wu, Peng Tang, Shifei Li, Shushu Wang, Yueyang Liang, Ling Zhong, Lin Ren, Ting Zhang, Yi Zhang
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2018
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/7abdbe810517401892ad3cece4d6b05b
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:7abdbe810517401892ad3cece4d6b05b
record_format dspace
spelling oai:doaj.org-article:7abdbe810517401892ad3cece4d6b05b2021-12-02T17:32:30ZA randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer10.1038/s41467-018-03210-22041-1723https://doaj.org/article/7abdbe810517401892ad3cece4d6b05b2018-02-01T00:00:00Zhttps://doi.org/10.1038/s41467-018-03210-2https://doaj.org/toc/2041-1723Triple-negative breast cancer (TNBC) is one of the most aggressive and difficult to treat types of breast cancer. Here, a phase 2 clinical trial in TNBC patients reveals that the addition of lobaplatin to docetaxel and epirubicin regime improves pCR and ORR rates with tolerable side-effects.Xiujuan WuPeng TangShifei LiShushu WangYueyang LiangLing ZhongLin RenTing ZhangYi ZhangNature PortfolioarticleScienceQENNature Communications, Vol 9, Iss 1, Pp 1-8 (2018)
institution DOAJ
collection DOAJ
language EN
topic Science
Q
spellingShingle Science
Q
Xiujuan Wu
Peng Tang
Shifei Li
Shushu Wang
Yueyang Liang
Ling Zhong
Lin Ren
Ting Zhang
Yi Zhang
A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer
description Triple-negative breast cancer (TNBC) is one of the most aggressive and difficult to treat types of breast cancer. Here, a phase 2 clinical trial in TNBC patients reveals that the addition of lobaplatin to docetaxel and epirubicin regime improves pCR and ORR rates with tolerable side-effects.
format article
author Xiujuan Wu
Peng Tang
Shifei Li
Shushu Wang
Yueyang Liang
Ling Zhong
Lin Ren
Ting Zhang
Yi Zhang
author_facet Xiujuan Wu
Peng Tang
Shifei Li
Shushu Wang
Yueyang Liang
Ling Zhong
Lin Ren
Ting Zhang
Yi Zhang
author_sort Xiujuan Wu
title A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer
title_short A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer
title_full A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer
title_fullStr A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer
title_full_unstemmed A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer
title_sort randomized and open-label phase ii trial reports the efficacy of neoadjuvant lobaplatin in breast cancer
publisher Nature Portfolio
publishDate 2018
url https://doaj.org/article/7abdbe810517401892ad3cece4d6b05b
work_keys_str_mv AT xiujuanwu arandomizedandopenlabelphaseiitrialreportstheefficacyofneoadjuvantlobaplatininbreastcancer
AT pengtang arandomizedandopenlabelphaseiitrialreportstheefficacyofneoadjuvantlobaplatininbreastcancer
AT shifeili arandomizedandopenlabelphaseiitrialreportstheefficacyofneoadjuvantlobaplatininbreastcancer
AT shushuwang arandomizedandopenlabelphaseiitrialreportstheefficacyofneoadjuvantlobaplatininbreastcancer
AT yueyangliang arandomizedandopenlabelphaseiitrialreportstheefficacyofneoadjuvantlobaplatininbreastcancer
AT lingzhong arandomizedandopenlabelphaseiitrialreportstheefficacyofneoadjuvantlobaplatininbreastcancer
AT linren arandomizedandopenlabelphaseiitrialreportstheefficacyofneoadjuvantlobaplatininbreastcancer
AT tingzhang arandomizedandopenlabelphaseiitrialreportstheefficacyofneoadjuvantlobaplatininbreastcancer
AT yizhang arandomizedandopenlabelphaseiitrialreportstheefficacyofneoadjuvantlobaplatininbreastcancer
AT xiujuanwu randomizedandopenlabelphaseiitrialreportstheefficacyofneoadjuvantlobaplatininbreastcancer
AT pengtang randomizedandopenlabelphaseiitrialreportstheefficacyofneoadjuvantlobaplatininbreastcancer
AT shifeili randomizedandopenlabelphaseiitrialreportstheefficacyofneoadjuvantlobaplatininbreastcancer
AT shushuwang randomizedandopenlabelphaseiitrialreportstheefficacyofneoadjuvantlobaplatininbreastcancer
AT yueyangliang randomizedandopenlabelphaseiitrialreportstheefficacyofneoadjuvantlobaplatininbreastcancer
AT lingzhong randomizedandopenlabelphaseiitrialreportstheefficacyofneoadjuvantlobaplatininbreastcancer
AT linren randomizedandopenlabelphaseiitrialreportstheefficacyofneoadjuvantlobaplatininbreastcancer
AT tingzhang randomizedandopenlabelphaseiitrialreportstheefficacyofneoadjuvantlobaplatininbreastcancer
AT yizhang randomizedandopenlabelphaseiitrialreportstheefficacyofneoadjuvantlobaplatininbreastcancer
_version_ 1718380257138966528

Ejemplares similares